Alzheimer's disease (AD) is a progressive neurodegenerative disorder that currently affects 36 million 2 people worldwide with no effective treatment available. Development of AD follows a distinctive 3 pattern in the brain and is poorly modelled in animals. Therefore, it is vital to widen both the spatial 4 scope of the study of AD and prioritise the study of human brains. Here we show that functionally 5 distinct human brain regions show varying and region-specific changes in protein expression. These 6 changes provide novel insights into the progression of disease, novel AD-related pathways, the 7 presence of a 'gradient' of protein expression change from less to more affected regions, and the 8 presence of a 'protective' protein expression profile in the cerebellum. This spatial proteomics 9 analysis provides a framework which can underpin current research and opens new avenues of interest 10 to enhance our understanding of molecular pathophysiology of AD, provides new targets for 11 intervention and broadens the conceptual frameworks for future AD research. 12 13 14 15
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by progressive 1 dementia 1,2 . Accumulation of Aβ peptide and microtubule-associated protein tau, which exhibits 2 hyperphosphorylation, and oxidative modifications into so-called 'plaques' and 'tangles' are 3 considered to be central to the pathology of AD 3 . Other prominent features of AD include early 4 region-specific decline in glucose utilisation and mitochondrial dysfunction and consequently 5 depleted ATP production and increased reactive oxygen species production in neurons 4 . 6
Excitotoxicity in the AD brain arising from altered glutamatergic signalling 5 , and dysregulation in 7 other neurotransmitters has also been documented, including abnormalities of adrenergic, serotonergic 8 and dopaminergic neurotransmission 6 . In response to pathological stimuli associated with AD, 9 inflammatory events mediated through both innate and cell-mediated immune mechanisms are also 10 present 3 . 11
Despite an increase in research into the underlying pathology of AD over the last decade, there 12
remains controversy around what underpins this disease process, which in turn affects the pipeline of 13 new disease modifying agents. There remains a lack of detailed mechanistic knowledge about what 14 happens in the human brain in AD. This is exacerbated by the fact that different brain regions develop 15 pathology at different times in the disease process, adding a spatial element to the disease which is not 16 captured by work in cell culture models and is often overlooked in human studies, which tend to focus 17 on single regions. Animal models also fail to capture the full disease process, at either the behavioral 18 or biochemical levels 7 , such that translation of both basic biological findings and/or the activity of 19 potential disease-modifying interventions from animals into humans is relatively unsuccessful. While 20 there have been several studies which have focused on the transcriptome in human AD, there is a 21 wealth of evidence that suggests many protein expression changes in biological systems can occur 22 independently of transcript-level regulation, and that studying the proteome can prove new insights on 23 the regulation of functionally active molecules in a given biological or disease state 8 . 24
Mass spectrometry based proteomics has been recognised as a powerful tool with the potential to 25 uncover detailed changes in protein expression 9 . To date, however, there are few studies of protein 26 expression in AD carried out using human brain tissue, and those that exist typically examine a single 27 AD affected brain region 10,11 , and use different patient cohorts and analytical methods that makes 28 between-region comparisons difficult. Such studies also frequently use either small numbers of 29 samples (n<4) or cohorts poorly matched for age or tissue post-mortem delay 10, 12, 13 . This study aims to 30 overcome some of these existing limitations by providing a spatially-resolved analysis of protein 31 expression in six regions of human control and AD-affected brain in well matched, short post-mortem 32 delay tissue. 33
Results

1
In this study, we analysed six functionally distinct regions of human post-mortem brain; hippocampus 2 (HP), entorhinal cortex (ENT), cingulate gyrus (CG), sensory cortex (SCx), motor cortex (MCx), and 3 cerebellum (CB), by mass spectrometry to gain a more comprehensive understanding of protein 4 expression changes within the AD brain. These regions were selected to represent parts of the brain 5 known to be heavily affected (HP, ENT, CG), lightly affected (SCx, MCx) and relatively 'spared' 6 (CB) during the disease process. Donors were well matched for age and post-mortem delay times 7 were short, with no significant difference between cases and control. Donor data is provided in 8 Supplementary Table 1 . Relative protein expression was determined using an isobaric tagging 9 approach followed by 2-dimensional liquid chromatography and mass spectrometry. Peptide-level 10 data were then analysed using a Bayesian model that infers a posterior probability distribution for the 11 relative levels of each protein between 'cases' and 'controls' based on the underlying relative peptide 12 levels. To promote sharing and usage of these data, we have developed a searchable web interface that 13 hosts all of our results (www.manchester.ac.uk/dementia-proteomes-project; described in 14 Supplementary Information), which also includes Bayesian probability distributions for each protein 15 across all individual brains examined in this study. The complete workflow is illustrated in Figure 1 . 16
The complete processed data for each region (at protein identification FDR <1%) can be found in 17 Supplementary Table 2 . Raw mass spectral data can be accessed via PRIDE, with initial search 18 outputs prior to Bayesian modelling available via the Open Science Framework at DOI 19 10.17605/OSF.IO/6BXJQ (Supplementary methods). 20 21 22 Figure 1. Proteomics workflow. Selected brain regions were pre-dissected prior to storage at -80°C until 1 analysis. Each region was lysed, and protein assigned to an iTRAQ 8plex. Following digestion and labelling, 2 samples were pooled, peptides fractionated by High-pH reverse phase chromatography and fractions analysed 3 by standard LC-MS/MS methods. Peptides were identified and quantified based on their iTRAQ reporter area; 4 relative protein quantification was inferred from these values using a Bayesian model. All data are deposited in 5 a searchable online database.
7
Each brain region was analysed in isolation, adding strength to our comparison of protein expression 8 changes across multiple regions, since these were identified and quantified independently. Combining 9 all protein identifications (at 1% false discovery rate) across the six experiments yielded a total of 10 5,825 unique protein identifications across all regions. In our data, 990 proteins were quantified with 11 only one or two spectra in any single region, and were subsequently omitted from our downstream 12 cross-regional comparison in order to retain the proteins with the most precise quantification -13 optimisation data suggests that when the same sample is split and processed independently, >99% of 14 proteins are defined as not being significantly different above this threshold (data not shown). 15
However, many of these will be quantified correctly (we have previously validated expression 16 changes based on a single spectrum, e.g. p53 in 8 ), and as such these data have been included in 17 Supplementary Table 2 and our online database. We thus quantified a total of 4,835 distinct proteins 18 in at least one brain region, among which 3,302 proteins were common to at least three regions, and 19
1,899 to all six regions ( Fig. 2a ). These data allow us to a) define protein changes as a result of AD in 20 any given region of the human brain being studied, and b) identify differences in how distinct brain 21 regions are affected in AD, and by extension protein changes which occur in multiple regions of the 22 AD brain. Comparison of the total number of proteins whose expression is altered in each region reveals, 2 perhaps unsurprisingly, that the more severely affected areas in AD (HP, ENT, CG) show the largest 3 number of changes in protein expression (~30% of quantified proteins), while less affected regions 4 (MCx, SCx) have fewer changes (11-13%). Strikingly, the CB, which many think to be pathologically 5 'unaffected', shows a substantial number of protein changes (20%; Fig. 2b ). This observation 6 accurately recapitulates data from our previous study of the metabolome on these brain samples 14 . 7
Unsupervised hierarchical clustering of protein expression changes from all six regions demonstrates 8 that the changes observed in CB are distinct from those seen in the affected HP, CG and ENT ( Fig.2c) . 9 This is supported by an Edwards-Venn representation of the data which shows that 120/403 (29.8%) 10 of changes in CB are not seen elsewhere ( Fig.2d ; Supplementary Table 3 ). While it has long been 11 reported that the CB in AD can contain amyloid plaques 15 , it is considered to be relatively 'spared' in 12
AD. There is a lack of neurofibrillary tangles in cerebellum 16 , and this region does not appear to 13 develop significant neuronal loss, such that this region is often used as a control in imaging studies of 14 the AD brain 17,18 . However, recent work by Guo et al. suggests a distinct pattern of cerebellar atrophy, 15 which spreads from intrinsic connectivity networks within the cerebrum 19 , and alterations in 16 cerebellar glucose metabolism have been reported in late stages of the disease 20,21 . Our data strongly 17 suggest that the CB is heavily affected by AD at the molecular level, at least in late stage disease, and 18 is so to a greater extent than other regions associated with later degeneration such as MCx or SCx, 19
where protein changes were fewer and encompass those seen in the more severely affected regions. 20
That the changes in CB are different from those seen elsewhere in the brain raises the possibility that, 21 rather than being 'spared', the CB is affected in a different way to other brain regions and that, given 22 it shows little pathology, these changes may reflect some level of active protection. 23 24 Hereinafter, we refer to HP, ENT and CG as the severely affected, and MCx and SCx as the less 25 affected regions based on the number of significantly altered proteins and pathways observed within 26 this study. 27 28 Unsupervised clustering of brain regions based on their protein expression, by performing a 29 dimensionality reduction on these data using isomeric feature mapping (Isomap), clearly shows this 30 hypothesized 'evolution' of the disease from the least affected cortical regions to the most affected, 31 with cerebellum following a distinct pathway from the inception of disease (Figure 2e ). This non-32 linear approach has been shown to be an improvement over the more standard PCA approach for 33 analysis of gene and signalling networks 22 . These data also further support our previous observation 34 that CB stands out as a single, uniquely affected brain region based on the distinctive patterns of 35 changes found here while the other regions line up along the same vector in accordance with disease 1 severity. Previous studies using gene co-expression networks and transcriptomics analysis have 2 demonstrated a pattern where the molecular signatures in less-affected areas of the brain overlap with 3 but are less marked than the grossly affected areas, and have implied that these overlapping changes 4 represent those which occur early in AD-related neurodegeneration 23 . Our data at the protein level 5 would support this conclusion -the less affected regions (MCx and SCx) contain very few protein 6 changes which are not seen elsewhere, and a clustering analysis suggests that these regions are simply 7 at an earlier stage down a similar pathway. Therefore, our data shows that by comparing more and 8 less affected brain regions in a multi-regional approach we can observe different stages of the same 9 disease process, enabling identification of early molecular changes, even in patients with late-stage 10 disease. 11
12
To probe the differences in AD-related protein expression between brain regions in more mechanistic 13 detail, we performed a pathway enrichment analysis for all differentially expressed proteins for each 14 region. Such analyses enable us to visualise which processes are affected in the AD brain, and also 15 Reflecting the individual protein expression data, HP and CG showed the highest number of 20 biological pathways being affected by AD. The changes in specific molecular pathways were 21 comparable between HP, ENT, and CG. CB, on the other hand, showed altered regulation of a set of 22 molecular pathways with limited overlap with those affected in the other five brain regions, again 23
arguing for the presence of a distinct cellular response to disease in this region. 24
25
One of the most consistent features across all brain regions was a significant change in proteins and 26 pathways involved with the innate immune response. In AD, aggregates of Aβ can trigger both 27 pathogen-associated and initiate immune responses, and a persisting elevation of Aβ may elicit a 28 chronic reaction of the innate immune system 24 . In this study, we observed strong evidence for the 29 global activation of the innate immune response, including of the acute-phase response, the 30 complement system (classical and alternative pathways) and the coagulation system, consistent with 31 widespread neuroinflammation, suggesting that this may be a relatively early (prior to atrophy) event 32
in pathogenesis. Previous studies have also implicated complement family proteins as potential AD 33 biomarkers 25 , and GWAS studies have identified AD risk loci in a number of complement pathway 34 genes 26-28 . It is worthy of note that these studies do not directly inform on the activation state of the 35 complement pathway, and indeed in our study we see upgregulation of SerpinG1, which inhibits 1 complement C4 cleavage by C1 and MASP2, as well as increased levels of C4, C3 and various 2 regulators in AD. While it is highly likely that dysregulation of this pathway plays a role in AD, the 3 precise nature of this role remains to be determined. Overall, HP, ENT and CG showed substantive 4 evidence for a broader spectrum of changes in immune responses compared to MCx, SCx and CB. 5
These included specific cellular pathways including granulocyte adhesion and dendritic cell 6 maturation ( Fig. 3a-f , Supplementary Data Table 4 and 5), implying that the innate immune system 7 becomes activated early, and that the adaptive immune response plays a role later in the disease 8 process. However the interplay between these two systems is complex and it is yet to be determined if 9
these changes are a cause, or a consequence of other aspects of AD pathogenesis 29 .
11
This pathway-level analysis also identified signaling pathways involved in apoptosis and cell cycle 12 regulation as being widely dysregulated in severely affected regions of AD brain, including the 13 HIPPO, ERK/MAPK, PI3K/AKT, and Wnt/β-catenin pathways ( Fig.3a We also observed both global and regional metabolic impairments in the AD brain. Defects in brain 1 metabolism and energetics are central to the pathogenesis of AD as evidence by epidemiological, 2 neuropathological, and functional neuroimaging studies 31 . The AD brain characteristically exhibits 3 defective cerebral perfusion 32 and glucose uptake 33 , which is believed to underlie hypometabolism and 4 cognitive decline 34 . Alterations in pathways of monosaccharide/glucose metabolism are highly 5 significant in severely affected brain regions and CB ( Fig.3a -f , Supplementary Data Table 4 ), 6 consistent with our previous finding of elevated free glucose levels in AD brain 21 . TCA enzyme 7 abundance was generally decreased in all regions of AD brain, going some way to explaining the 8 previously observed shift from primarily aerobic glycolysis (i.e. glycolysis followed by complete 9 oxidation in mitochondria) to the ketogenic/fatty acid β-oxidation pathway, with impaired 10 mitochondrial bioenergetics 35 . Severely affected brain regions also showed substantial alterations in 11 signals related to altered regulation of neurotransmitters/hormones (noradrenaline/adrenaline, 12 dopamine, and aldosterone) that were not observed in less affected regions. While this might suggest 13 that altered neurotransmitter biology is a late or downstream process in pathogenesis, it is notable that 14 the enzymes in a key upstream pathway of neurotransmitter production which results in the 15 production of tetrahydrobiopterin (BH4), a precursor of dopamine, noradrenaline and serotonin, is 16 significantly upregulated in all regions studied. Previous work has suggested a decrease in BH4 levels 17 in AD brain 36 provides a surprising finding, even more so when one observes that these changes are distinct from 24 those manifest elsewhere. To investigate this population of protein changes further, we analysed 25 proteins uniquely affected in CB using both DAVID and STRING. These analyses supported our 26 earlier global pathway analysis in demonstrating that CB additionally showed alteration in 27
Semaphorin and ciliary neurotrophic factor (CNTF) pathway members which play important roles in 28 neuronal survival and neurodevelopment/neuronal regeneration ( Fig.3c and Fig.4a, b) . SEMA7A, 29
shown here to be upregulated in CB of AD brains, is known to be involved in repair of the glial scar 30 following spinal cord injury and to play a role in the development of multiple sclerosis, but has not 31 previously been linked to the disease process in AD 37 . CB also showed a significant reduction in 32 levels of both nuclear and mitochondrial aminoacyl-tRNA synthetases. In CB, significantly depleted 33 aminoacyl tRNA synthetases, including those encoded in the mitochondrial genome as well as those 34 from the nuclear genome ( Fig.3c and Supplementary Data Table 3 ), could disrupt translational 35 fidelity, leading to accumulation of misfolded proteins 38 . However, these proteins are multifunctional. 36
For example, Ishimura et al. have shown that misregulated tRNA processing can lead to 1 neurodegeneration 39 , and tRNA synthetases have also been shown to be mediators of inflammation 2 40 thus downregulating these proteins may confer some level of protection. This finding could also 3 provide a supportive mechanism for the hypothesis that ribosomal dysfunction is an early event in 4 AD 41 . Taken together with its known roles in inflammation and signaling, and in several other 5 neurodegenerative disorders 42 , our data suggest that the role of tRNA synthetases in Alzheimer's 6 disease is worthy of significant further investigation. 7 8 One of the most distinct changes observed in this CB-specific analysis was that a much greater 9 number of proteins of electron transport chain (ETC) complex 1 were consistently more reduced in 10 abundance (Fig.4b , c Supplementary Data Table 5 ) than was found in other areas. Furthermore, CB 11 showed increases in oxidative defense proteins involved in glutathione redox reactions and ascorbate 12 recycling (Fig.3c ). These data provide strong additional evidence for a protective mechanism in CB 13 that decreases ROS-production by ETC while simultaneously increasing ROS defenses. Another 14 interesting observation in CB was the activation of a Purine Ribonucleosides Degradation pathway, 15 which could not only contribute substrate to the pentose phosphate pathway, but also participate in 16 guanine/guanosine production in this brain region. Combined with the observed activation of Guanine 17
and Guanosine Salvage I pathway, and an increase in guanosine level in CB as previously reported by 18 our metabolomics analysis 14 , these changes may also confer a previously unknown neuroprotective 19 effect in this brain region 43 . 20 21 Figure 4. CB-specific biological processes in AD brain. a) 120 proteins that showed CB-specific 22 alterations were enriched for molecular processes in STRING using default setting. Each node 23 represents a protein, and proteins involved in b) significantly enriched pathways were highlighted. c) 24
Dysregulation of the mitochondrial electron transport chain was highlighted by pathway analysis, and 25 It is well established that CB does not display extensive apoptotic activation seen elsewhere in the 4 brain in Alzheimer's disease, which is unsurprising given its structurally unaffected status. Our 5 findings indicate that the lack of significant neurodegeneration in this region is not merely due to the 6 absence of an apoptotic signal (e.g. Tau tangles) but instead that CB actively induces a unique pattern 7 of upregulated neuronal survival pathways alongside protection against oxidative and inflammatory 8 damage; a protective mechanism of gene/protein expression which limits disease-related degeneration 9 in this region. 10 11 Given the apparently similarity in protein expression which we seen wining each group (severely 12 affected and less affected), we next attempt to identify key regulators of what appears to be a 13 coordinated alteration in protein expression across the brain in response to AD. We performed a 14 correlation network analysis to identify key nodes which may be responsible for the programme of 15 protein expression observed, using the Cytoscape ModuLand plug-in 44 . The resulting correlation 16 network is shown in Figure 5a . Each cluster is coloured differently according to a distinct meta-node, 17
the key regulators of which can be determined by visualizing higher levels of this hierarchy (Fig. 5b) . 18
Using this method, we can identify the most influential genes in this correlation network which we 19 hypothesize to be key regulators of protein expression during the pathogenesis of AD. It is noteworthy 20 that in this correlation matrix we are aiming to correlate what we believe to be two distinct processes 21 -AD pathogenesis (seen in HP, ENT, CG, MCx and SCx) and a protective programme that we 22 observe in CB. By overlaying protein expression data onto this network, we can identify which nodes 23 are associated with which process. This overlay ( Fig. 5c-h) clearly demonstrates that the correlation 24 network is mainly constructed from proteins involved in AD pathogenesis in the affected regions -25 few proteins in the network are changed in CB despite the relatively large number of CB proteins 26 which we observe to be changed in the complete dataset. This is to be expected as CB-specific protein 27 changes have limited correlation to the remainder of the dataset. This network is therefore likely to 28 provide a good representation of the key events in AD pathogenesis, and reveals four proteins with the 29 most overall influence on the correlated expression networks: STXBP1 (syntaxin binding protein 1); 30 CRMP1, (collapsin response-mediator protein 1); ACTR10, (actin-related protein 10 homologue); and 31 AMPH (amphiphysin). 32 33 STXBP1 is the regulator with the most influence in this network. It is reportedly upregulated in AD 45 , 34 has been linked to NFTs 46 and may interact with PS1 47 . It also plays a major role in neurotransmitter 35 release. STXBP1 thus provides a potential mechanistic explanation for our observation that pathways 1 of neurotransmitter metabolism including dopamine-, noradrenaline-, and serotonin-related signalling 2 showed significant changes in severely affected regions and SCx, but not in MCx or CB. Another 3 important regulator of the network, CRMP1, is part of the semaphorin signalling pathway which is 4 known to guide axons in developing nervous tissue and participates in shaping of neural circuits 48 . 5 ACTR10 may affect prion susceptibility through its involvement in prion propagation and clearance 49 , 6 and has been identified by large scale computational network analyses as one of a large number of 7 potentially important genes in hippocampal ageing, but our finding is novel in AD 50 . The 4 th key 8 network regulator identified here, AMPH, is a candidate AD risk gene that may participate in 9 receptor-mediated endocytosis and hence be involved in APP metabolism/clearance 51 . Our finding 10 that these four genes appear to be central to various pathological processes known to be involved in 11 AD development is important, and suggests that further work should be performed to focus on the role 12 of these potentially key mediators of Alzheimer's disease progession. Aβ peptide generated as a proteolytic product of the Amyloid precursor protein (APP) we examined 7 our data for information about the levels and distribution of these molecules. We found no marked 8 change in APP levels overall but significantly elevated Aβ peptide levels ( Supplementary Figure 2a-9 b), consistent with previous reports 52 . The extent of the increase in Aβ between regions does not 10 appear to follow a gradient of 'affectedness', albeit there may be a more pronounced increase in 11
hippocampus. There is no way to determine the primary structure of the Aβ peptide(s) present in each 12 region from these data. Interestingly, while in the AD group almost all samples showed uniformly 13 high levels of Aβ peptide, there was marked variation in levels in control samples (Supplementary 14 Figure 2c ). While the quantification of Aβ is necessarily from one peptide, these data emanate from 15 between 5 and 12 unique spectra in each sample we consider this observation is likely robust. This 16 variability is therefore likely to be due to inherent variations in the control population. Although all 17 patients in this group were asymptomatic, it is likely that varying degrees of prodromal disease could 18 have been present, given their age. This is most noticeable in our control 115. While initially 19 assigned as a control, a pathological re-examination performed as a result of the findings of this study 20 and our previous metabolomics analyses 14 re-classified this individual as a Braak II pre-clinical AD 21 patient. This patient has the highest level of Aβ of all of the control samples and interestingly appears 22 to demonstrate some AD-related changes both in their metabolome and in some of the proteins which 23 we observe to be changed in symptomatic disease. This observation supports the idea that increases in 24
Aβ levels may reflect varying degrees of prodromal disease in these elderly controls. It also 25 demonstrates that studies of the type performed here in earlier stage presymptomatic patients will be 26 critical to further tease out the very earliest events in AD pathogenesis. 27
28
In summary, this study provides a map of molecular changes that are present in human post-mortem 29 brain tissue in patients with AD and matched controls, providing insights into the brain region 30 specificity of disease at two levels; individual proteins and pathways. We observed global 31 perturbation of protein expression in all six regions of the AD brain which we studied. An association 32 between extent of molecular changes and affectedness was observed for five regions, allowing us to 33 delineate probably 'early' and 'late' changes in protein expression and revealing previously novel 34 involvement of several pathways and processes. The sixth region, CB, showed an unexpectedly distinct pattern of protein changes, suggestive of induction of a protective response. Correlation 1 network analysis identified four candidate genes STXBP1, CRMP1, ACTR10, and AMPH which may 2 underpin significant portions of the protein expression response to AD. Finally, we recognize that 3 these data have significant value to the community and that other researchers will no doubt wish to 4 assess the status of other AD-related changes not discussed here. As such we have provided all results 5 in an accessible format via a freely-available, searchable on-line database, to allow others to probe 6 specific pathways or individual proteins and their expression in regions across the human Alzheimer's 7 disease brain and matched controls. 
